[go: up one dir, main page]

WO2005100556A3 - Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes - Google Patents

Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes Download PDF

Info

Publication number
WO2005100556A3
WO2005100556A3 PCT/US2005/012243 US2005012243W WO2005100556A3 WO 2005100556 A3 WO2005100556 A3 WO 2005100556A3 US 2005012243 W US2005012243 W US 2005012243W WO 2005100556 A3 WO2005100556 A3 WO 2005100556A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
wild
type
cleavage
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/012243
Other languages
English (en)
Other versions
WO2005100556A2 (fr
Inventor
Sandra Waugh Ruggles
Jack Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Priority to EP05735778A priority Critical patent/EP1735438A2/fr
Publication of WO2005100556A2 publication Critical patent/WO2005100556A2/fr
Publication of WO2005100556A3 publication Critical patent/WO2005100556A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention a trait à des procédés pour la création et l'utilisation de protéases de mutéine à spécificité modifiée pour des molécules cibles dont elles assurent le clivage. L'invention a également trait à des procédés d'utilisation de granzyme B de type sauvage et de mutéine pour le ciblage de protéines de récepteur VEGF pour le traitement de maladies, tells que le cancer. Le clivage de récepteur VEGF au niveau de certaines séquences substrat avec des protéases de granzyme B de type sauvage et de mutéine constitue un procédé pour le traitement de pathologies associées à l'angiogenèse.
PCT/US2005/012243 2004-04-12 2005-04-12 Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes Ceased WO2005100556A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05735778A EP1735438A2 (fr) 2004-04-12 2005-04-12 Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56167104P 2004-04-12 2004-04-12
US60/561,671 2004-04-12

Publications (2)

Publication Number Publication Date
WO2005100556A2 WO2005100556A2 (fr) 2005-10-27
WO2005100556A3 true WO2005100556A3 (fr) 2006-01-19

Family

ID=35150553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012243 Ceased WO2005100556A2 (fr) 2004-04-12 2005-04-12 Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes

Country Status (2)

Country Link
EP (1) EP1735438A2 (fr)
WO (1) WO2005100556A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290757B2 (en) 2006-07-05 2016-03-22 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US9359598B2 (en) 2004-04-12 2016-06-07 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047995A2 (fr) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Protéases modifiées qui inhibent l'activation du complément
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
CA2849669A1 (fr) * 2011-09-23 2013-03-28 Pharmedartis Gmbh Nouveaux variants de la serine protease
CA3084907A1 (fr) * 2017-12-21 2019-06-27 Ab Enzymes Oy Variants de cellulase fongique
WO2021241719A1 (fr) * 2020-05-28 2021-12-02 中外製薬株式会社 Variant de granzyme b amélioré
CN111944790B (zh) * 2020-07-01 2022-09-09 深圳润康生态环境股份有限公司 中性蛋白酶基因、中性蛋白酶及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022243A1 (en) * 2000-06-02 2002-02-21 Harris Jennifer L. Profiling of protease specificity using combinatorial fluorogenic substrate libraries
WO2004031733A2 (fr) * 2002-10-02 2004-04-15 Catalyst Biosciences Procedes de production et de criblage de proteases a specificite modifiee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022243A1 (en) * 2000-06-02 2002-02-21 Harris Jennifer L. Profiling of protease specificity using combinatorial fluorogenic substrate libraries
WO2004031733A2 (fr) * 2002-10-02 2004-04-15 Catalyst Biosciences Procedes de production et de criblage de proteases a specificite modifiee

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRIEDRICH R ET AL: "Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 3, 18 January 2002 (2002-01-18), pages 2160 - 2168, XP002244714, ISSN: 0021-9258 *
HARRIS J L ET AL: "Definition and redesign of the extended substrate specificity of granzyme B", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 273, no. 42, 16 October 1998 (1998-10-16), pages 27364 - 27373, XP002296677, ISSN: 0021-9258 *
RUGGLES SANDRA WAUGH ET AL: "Characterization of structural determinants of granzyme B reveals potent mediators of extended substrate specificity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 29, 16 July 2004 (2004-07-16), pages 30751 - 30759, XP002304824, ISSN: 0021-9258 *
WAUGH S M ET AL: "The structure of the pro-apoptotic protease granzyme B reveals the molecular determinants of its specificity", NATURE STRUCTURAL BIOLOGY, NEW YORK, NY, US, vol. 7, no. 9, September 2000 (2000-09-01), pages 762 - 765, XP002307284, ISSN: 1072-8368 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359598B2 (en) 2004-04-12 2016-06-07 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US9290757B2 (en) 2006-07-05 2016-03-22 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Also Published As

Publication number Publication date
EP1735438A2 (fr) 2006-12-27
WO2005100556A2 (fr) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005110453A3 (fr) Clivage du vegf et du récepteur du vegf par mt-sp1 de type sauvage et mutant
WO2004031733A3 (fr) Procedes de production et de criblage de proteases a specificite modifiee
WO2005100556A3 (fr) Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes
WO2011036640A3 (fr) Réactifs à base de méganucléase et leurs utilisations pour traiter des maladies génétiques provoquées par des mutations de changement de phase/ non sens
WO2004013280A3 (fr) Silençage genique a mediation par arnsi specifique des alleles
EP2281841A3 (fr) Biomarqueurs pour la présélection des patients pour la thérapie anti-IGF1R
EP2062980A3 (fr) Méthodes et séquences pour supprimer préférentiellement l'expression du gène huntingtin muté.
WO2002031134A3 (fr) Nouveaux genes de serine protease apparentes a la dppiv
WO2001071009A3 (fr) Imagerie optique corps entier de l'expression genique et utilisations correspondantes
LT2012062A (lt) Kompozicijos, būdai ir susiję panaudojimai, skirti modifikuotos dnr skaldymui
WO2006068794A3 (fr) Genes clostridiaux genetiquement modifies, proteines codees par ces genes modifies et utilisations de ceux-ci
WO2003097810A3 (fr) Nitrilases, acides nucleiques les codant et leurs procedes de production et d'utilisation
EP1947180A4 (fr) Ver à soie transgénique capable de produire un anticorps et méthode de production dudit anticorps
WO2005058945A3 (fr) Variants genetiques codant pour des proteines issues de la voie metabolique de produits chimiques fins
WO2005086768A3 (fr) Production amelioree de proteines fonctionnelles a partir de genes defectueux
WO2003004628A3 (fr) Procede de purification d'une enzyme, enzyme ainsi produite et purifiee et utilisation de cette enzyme
WO2006063055A3 (fr) Conjugues enzymatiques utilises en tant qu'agents detoxifiants
WO2005069913A3 (fr) Expression de proteines mammiferes dans pseudomonas fluorescens
ATE535530T1 (de) 7-substituierte camptothecin- und camptothecin- analoga und herstellungsverfahren dafür
WO2008073688A3 (fr) Système d'expression améliorée pour l'arginase i humaine recombinante
EP2067857A4 (fr) Procede de production de dipeptide
WO2003012116A3 (fr) Polypeptides et acides nucleiques de caax prenyl protease, et leurs methodes d'utilisation
Simkus et al. Correlation between recombinase activating gene 1 ubiquitin ligase activity and V (D) J recombination
WO2002033093A3 (fr) Molecules de l'aggrecanase
WO2004019959A3 (fr) Enzymes de reparation de l'adn

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005735778

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005735778

Country of ref document: EP